Nirmatrelvir-ritonavir showed no reduction in hospitalization or death within 28 days for higher-risk adults in community trials.
New Study Questions Early Use of Paxlovid for Vaccinated Patients
In community-based trials involving higher-risk adults with recent SARS-CoV-2 infection, adding nirmatrelvir-ritonavir to usual care did not…
Getting vaccinated changes how your body fights the virus, and this new research shows that taking Paxlovid early might not be necessary for…
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19
Paxlovid prescription linked to lower hospitalization risk in adults with COVID-19
An observational study of eligible US adults with COVID-19 found those prescribed Paxlovid were 51% less likely to be hospitalized. The stud…
Adults prescribed Paxlovid for COVID-19 were 51% less likely to be hospitalized compared to those who did not get the medication.
Clinical trials examine COVID-19 rebound after nirmatrelvir/ritonavir versus placebo treatment
Does the COVID-19 rebound risk change with or without Paxlovid treatment?
Randomized, double-blind trials at U.S. and international sites investigated COVID-19 rebound following nirmatrelvir/ritonavir treatment ver…
Two rigorous clinical trials are investigating whether Paxlovid treatment changes the risk of COVID-19 symptoms returning after patients sta…
Observational study finds low hospitalization and ED visit rates after Paxlovid treatment for COVID-19 in California
Did Paxlovid keep COVID patients in California out of the hospital?
An observational study of patients in California treated with Paxlovid for COVID-19 reported low rates of subsequent hospitalizations and em…
Paxlovid treatment for COVID-19 in California was linked to low rates of hospitalizations and emergency department visits, offering hope for…